

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Soffer Rochel</u> <hr/> (Last) (First) (Middle) 9559 COLLINS AVENUE, #1009S <hr/> (Street) MIAMI FL 33154 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/16/2024	3. Issuer Name and Ticker or Trading Symbol <u>Galera Therapeutics, Inc. [GRTX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,178,137 ⁽¹⁾⁽²⁾	D	
Common Stock	2,750,000 ⁽¹⁾⁽²⁾	I	See Footnote ⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person* <u>Soffer Rochel</u> <hr/> (Last) (First) (Middle) 9559 COLLINS AVENUE, #1009S <hr/> (Street) MIAMI FL 33154 <hr/> (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>ALPHA PHARMA Investments LLC</u> <hr/> (Last) (First) (Middle) 9559 COLLINS AVENUE, #1009S <hr/> (Street) MIAMI FL 33154 <hr/> (City) (State) (Zip)

Explanation of Responses:

1. Of the 5,928,137 Shares reported, 3,178,137 shares of common stock are held by Rochel Soffer individually and 2,750,000 shares of common stock are held by Alpha Pharma Investments LLC (collectively, the "Reporting Persons"). Rochel Soffer, as the sole member and beneficiary of Alpha Pharma Investments LLC has voting and dispositive power of Alpha Pharma Investments LLC.

2. The Reporting Persons disclaims beneficial ownership of all securities owned by Yair Schneid, the spouse of Rochel Soffer, except to the extent of their pecuniary interest therein, if any.

/s/ Rochel Soffer, Sole
Member of Alpha Pharma 05/15/2024
Investments LLC

/s/ Rochel Soffer 05/15/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.